Duloxetine in the treatment of adolescents with attention deficit/hyperactivity disorder: an open-label study

Mahmoudi-Gharaei, Javad; Dodangi, Nasrin; Tehrani‐Doost, Mehdi; Faghihi, Toktam

doi:10.1002/hup.1188

Cited by 18 publications

(17 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This issue has been studied in recent research that showed positive effects of a monotherapy with fluoxetine in patients with ADHD on aggression, inattention, and depressive symptoms (38). Moreover, an open‐label study in a small sample of adolescents with ADHD using duloxetine showed promising initial results and positive effects on inattention, hyperactivity, and oppositional behaviour (39). This finding is closely related to comorbid conduct problems, which are frequently observed in patients with ADHD.…”

Section: Discussionmentioning

confidence: 99%

Effects of tryptophan depletion on reactive aggression and aggressive decision‐making in young people with ADHD

Kötting

Bubenzer

Helmbold

et al. 2012

Acta Psychiatr Scand

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of tryptophan depletion on reactive aggression and aggressive decision‐making in young people with ADHD

Kötting

Bubenzer

Helmbold

et al. 2012

Acta Psychiatr Scand

View full text Add to dashboard Cite

show abstract

“…In another open trial, duloxetine was given to 13 adolescents with ADHD. A significant reduction in ADHD symptoms measured by CPRS-R was observed from week four (32).…”

Section: Discussionmentioning

confidence: 88%

Preliminary Investigation on Duloxetine Efficacy in the Treatment of Children With Attention-Deficit Hyperactivity Disorder

2015

Self Cite

View full text Add to dashboard Cite

Background: Stimulants are first-line agents for the treatment of attention-deficit/hyperactivity disorder (ADHD). Despite the impressive track record of stimulants in the treatment of ADHD, they fail in 25% of patients due to lack of efficacy or the emergence of unwanted side effects. Objectives: In this study, we investigated the efficacy and safety of duloxetine, a serotonin and norepinephrine reuptake inhibitor, in the treatment of children with attention-deficit hyperactivity disorder (ADHD). Patients and Methods:In an open label clinical trial, 13 children aged 6 -11 years diagnosed with ADHD were prescribed 30 mg/day duloxetine once daily by oral administration for six weeks. Conners Parent Rating Scale-Revised-Short form (CPRS-R-S) and the ADHD Rating Scale were used to assess the efficacy of the treatment. Results: Ten children with a mean age of 8.40 ± 1.67 years terminated the trial. A significant reduction in CPRS-R and its subscales was evident from week four of the study. In terms of side effects, duloxetine was generally safe and well tolerated. Conclusions: This preliminary assessment suggests that duloxetine may be a medication of interest in the treatment of children with ADHD. Further controlled studies with larger samples are required to evaluate the efficacy of duloxetine in treatment of children with ADHD.

show abstract

“…Duloxetine (repurposed emerging) was tested [42] in a singlearm trial on adolescents, lasting 6 weeks. Duloxetine dose was 60 mg/d.…”

Section: Serotonin-norepinephrine Reuptake Inhibitors (Snris)mentioning

confidence: 99%

Emerging drugs for the treatment of attention-deficit hyperactivity disorder (ADHD)

Pozzi

Bertella

Gatti

et al. 2020

Expert Opinion on Emerging Drugs

View full text Add to dashboard Cite

Introduction: Attention-deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder affecting up to 5.3% of children and 2.5% of adults depending on the country considered. Current pharmacological treatments for ADHD are based on stimulant or non-stimulant medications, targeting dopaminergic and noradrenergic systems in the frontal cortex and dopaminergic system in the basal ganglia. These drugs are effective and safe for the majority of patients, whereas about 20% of treated patients do not tolerate current therapies or experience insufficient efficacy. The adequate treatment of ADHD is necessary to allow a proper social placement and prevent the acquisition of additional, more severe, comorbidities. Areas covered: We conducted a review of the scientific literature and of unpublished/ongoing clinical trials to summarize the advances made in the last 10 years (2010-2020) for the pharmacological treatment of ADHD. We found many pharmacological mechanisms beyond dopaminergic and noradrenergic ones have been investigated in patients. Expert opinion: Some emerging drugs for ADHD may be promising as add-on treatment especially in children, amantadine to enhance cognitive functions and tipepidine for hyperactivity/impulsivity. Stand-alone emerging treatments for ADHD include viloxazine and dasotraline, which will soon have more clinical data available to support market access requests.

show abstract

Duloxetine in the treatment of adolescents with attention deficit/hyperactivity disorder: an open-label study

Abstract: The results of this open-label study suggest a promise of duloxetine in the treatment of youth with ADHD. Further controlled studies with larger samples are required to evaluate the efficacy of duloxetine in children and adolescents with ADHD.

Cited by 18 publications

References 31 publications

Effects of tryptophan depletion on reactive aggression and aggressive decision‐making in young people with ADHD

Effects of tryptophan depletion on reactive aggression and aggressive decision‐making in young people with ADHD

Preliminary Investigation on Duloxetine Efficacy in the Treatment of Children With Attention-Deficit Hyperactivity Disorder

Emerging drugs for the treatment of attention-deficit hyperactivity disorder (ADHD)

Contact Info

Product

Resources

About